168 related articles for article (PubMed ID: 16736978)
1. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
Lenz HJ
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):5-13. PubMed ID: 16736978
[TBL] [Abstract][Full Text] [Related]
2. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
Khalil MY; Grandis JR; Shin DM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
[TBL] [Abstract][Full Text] [Related]
3. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
4. Anti-EGFR therapy update: clinical experience and adverse event insights.
Harari PM
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):3-4. PubMed ID: 16736977
[No Abstract] [Full Text] [Related]
5. Nondermatologic adverse events associated with anti-EGFR therapy.
Sandler AB
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):35-40. PubMed ID: 16736981
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of cutaneous toxicities to EGFR inhibitors.
Lacouture ME
Nat Rev Cancer; 2006 Oct; 6(10):803-12. PubMed ID: 16990857
[TBL] [Abstract][Full Text] [Related]
8. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
9. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
[TBL] [Abstract][Full Text] [Related]
10. Biology of interactions: antiepidermal growth factor receptor agents.
Harari PM; Allen GW; Bonner JA
J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
[TBL] [Abstract][Full Text] [Related]
11. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
12. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
Astsaturov I; Cohen RB; Harari P
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1179-93. PubMed ID: 17020453
[TBL] [Abstract][Full Text] [Related]
13. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
14. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
15. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
16. Malassezia folliculitis presented as acneiform eruption after cetuximab administration.
Cholongitas E; Pipili C; Ioannidou D
J Drugs Dermatol; 2009 Mar; 8(3):274-5. PubMed ID: 19271376
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab-induced acne.
Molinari E; De Quatrebarbes J; André T; Aractingi S
Dermatology; 2005; 211(4):330-3. PubMed ID: 16286741
[TBL] [Abstract][Full Text] [Related]
18. [Unilateral acneiform rash in facial palsy].
Kerob D; Hennequin V; Bousquet G; Behm E; Lebbe C
Ann Dermatol Venereol; 2010 Nov; 137(11):727-9. PubMed ID: 21074658
[TBL] [Abstract][Full Text] [Related]
19. Severe acneiform eruption induced by cetuximab (Erbitux).
Lee JE; Lee SJ; Lee HJ; Lee JH; Lee KH
Yonsei Med J; 2008 Oct; 49(5):851-2. PubMed ID: 18972607
[TBL] [Abstract][Full Text] [Related]
20. Grover's disease induced by cetuximab.
Tscharner GG; Bühler S; Borner M; Hunziker T
Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
